ALT | Altimmune, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	8.18 - 8.75
52 Week Range	5.28 - 14.84
Beta	0.20
Implied Volatility	118.87%
IV Rank	44.31%
Day's Volume	4,724,621
Average Volume	3,045,690
Shares Outstanding	71,124,600
Market Cap	586,777,950
Sector	Healthcare
Industry	Biotechnology
IPO Date	2017-05-26

Valuation
Profitability
Growth
Health
P/E Ratio	-5.25
Forward P/E Ratio	N/A
EPS	-1.57
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	59
Country	USA
Website	ALT

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

ALT's peers: RVPH, ATHA, FBIO, ACAD, CABA, AKRO, TERN, MDGL, INZY, VKTX, AVXL, SAVA, INMB, BIVI, CGTX, ARDX, ZURA, HEPA, AVRO, VSTM, XFOR, GRTX, DAWN, HOOK

*Chart delayed

Analyzing fundamentals for ALT we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is passable. For more detailed analysis please see ALT Fundamentals page.

Watching at ALT technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, but short-term trend is bearish. More technicals details can be found on ALT Technicals page.